跳至主要内容
临床试验/2025-523549-92-00
2025-523549-92-00招募中4 期

Melatonin versus placebo for bipolar disorder - a double blinded randomised controlled trial (The M-bipolar RCT)

Region Hovedstaden1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2026年1月16日最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
发起方
入组人数
200
试验地点
1
主要终点
Mood stabilization will be measured by a mood instability score reflecting the daily variability in self-monitored mood collected via the Monsenso system

研究概览

简要总结

To conduct a 6-month RCT comparing effects of melatonin versus placebo on mood stabilisation and other critical patient outcomes in patients with bipolar disorder and to test whether principal effects are antimanic, antidepressant and/or prophylactic against relapse. Primary hypotheses: Add on melatonin improves mood stabilization compared with add on placebo.

入排标准

年龄范围
18 years 至 64 years(18-64 Years)
接受健康志愿者

入选标准

  • Bipolar disorder with diagnosis confirmed by SCAN interview
  • Age 18-70 years
  • Speaks and writes danish or english at a level equal to mothers tongue
  • Habile (i.e., able to give informed consent)

排除标准

  • Past intolerance to melatonin
  • Impaired renal or hepatic function
  • Women who are pregnant, breastfeeding or planning pregnancy in near future

结局指标

主要结局

Mood stabilization will be measured by a mood instability score reflecting the daily variability in self-monitored mood collected via the Monsenso system

Mood stabilization will be measured by a mood instability score reflecting the daily variability in self-monitored mood collected via the Monsenso system

次要结局

  • Hamilton D6, Pittsburgh Sleep Quality, Young Mania Rating Scale, Functioning Assessment Short Test (FAST), internet-based Cognition Assessment Tool (ICAT) and bloodbased inflammation markers in bloodsamples, hair cortisol and urine oxidative stress markers

研究者

发起方
Region Hovedstaden
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Lars Vedel Kessing

Scientific

Region Hovedstaden

研究点 (1)

Loading locations...

相似试验